首页> 外文期刊>Heart rhythm: the official journal of the Heart Rhythm Society >Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices
【24h】

Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices

机译:评估一种新的标准化方案,用于接受可植入心律失常设备的慢性抗凝患者的围手术期管理

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Perioperative management of oral anticoagulation (OAC) in patients receiving pacemakers or implantable cardioverter-defibrillators remains an issue of concern. Objective: We sought to evaluate the safety and the effect on the hospital length of stay of a new standardized protocol for perioperative management of OAC in this setting. Methods: The new standardized protocol classified patients according to a renewed evaluation of their thromboembolic (TE) risk. Briefly, patients were considered at moderate-to-high TE risk if they had a mechanical valvular prostheses irrespective of type and location or atrial fibrillation associated with a CHADS 2score of 2, mitral stenosis or previous stroke, and underwent device implantation without stopping OAC (OAC continued, n = 129). Complete interruption of OAC before surgery was performed in low-TE-risk patients (OAC interrupted, n = 82). A retrospective cohort of patients managed with a classic heparin-bridging strategy served as a control group, with 62 patients considered at moderate-to-high TE risk according to previous guidelines (receiving pre- and postoperative low-molecular-weight heparin) and 146 considered at low TE risk (receiving only low doses of postoperative low-molecular-weight heparin). Results: TE events were comparable between the 2 strategies. Patients entering the new standardized protocol had significantly lower rates of pocket hematoma (2.3% for OAC continued vs 17.7% for moderate-to-high TE risk bridging controls, P =.0001, and 0% for OAC interrupted vs 13% for low-TE-risk bridging controls, P .0001) and shorter hospital stays. A mean of 3.34 hospitalization days per patient were saved with the new standardized protocol, with an estimated cost savings of ?850.83 per patient. Conclusions: Implantation of the new standardized protocol resulted in a significant reduction in bleeding complications and hospital stays, with adequate protection against TE events and significant cost savings.
机译:背景:接受起搏器或植入式心脏逆转表纤维的患者口服抗凝(OAC)的围手术期管理仍然是一个令人关注的问题。目的:我们试图评估在此环境中OAC围手术期管理新标准化方案的安全性和对医院住院时间的影响。方法:根据对血栓栓塞(TE)风险的重新评估,新的标准化方案对患者进行了分类。简而言之,如果患者具有机械瓣膜假体,则考虑到中度至高度的风险,无论与chads 2score相关的类型和位置或房颤,二尖瓣狭窄或先前的笔触,而无需停止植入设备植入, OAC(OAC续,n = 129)。在低调风险患者中进行手术前的OAC完全中断(OAC中断,n = 82)。通过经典的肝素桥策略管理的一组患者队列作为对照组,根据先前的指南(接受前和术后低分子肝素),考虑了62名患者的中等至高度TE风险,146考虑到低风险(仅接受低剂量的术后低分子量肝素)。结果:两种策略之间的事件是可比的。进入新标准化方案的患者的口袋血肿率显着降低(OAC持续2.3%vs vs中等到高的TE风险桥接控制,P = .0001,OAC中断为0%,而低 - 13% Te风险桥接控制,P< .0001)和较短的医院。每位患者的平均住院时间为3.34天,并通过新的标准化方案节省了平均水平,估计成本节省为每位患者850.83。结论:植入新的标准化协议导致出血并发症和住院的大幅减少,并有足够的保护,以抵抗TE事件和大量成本节省。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号